Complementary technology to augment MDS Analytical Technologies'
cellular analysis capabilities
SUNNYVALE, CA, June 27 /CNW/ - MDS Analytical Technologies, a leader in
innovative solutions for drug discovery and life sciences research, today
announced it has acquired California-based Blueshift Biotechnologies
(Sunnyvale, CA) for $13 million. The acquisition of Blueshift Biotechnologies,
a developer of screening platforms for life sciences research and maker of the
IsoCyte(TM) benchtop laser scanning cytometer, expands MDS Analytical
Technologies' capabilities in cellular analysis, and further strengthens the
company's global sales and service offering.
High Content Screening (HCS) and High Content Analysis (HCA) are growing
trends in both pharmaceutical drug screening and life sciences research. MDS
Analytical Technologies' cellular imaging product line now includes imaging
systems and software that provide life sciences and drug discovery researchers
with a more complete solution to conduct HCS and HCA. Cellular imaging
provides intracellular information on compound effects for a large variety of
cellular processes. Blueshift Biotechnologies' IsoCyte(TM) instrument conducts
rapid image analysis of large populations of cells in a microtiter plate
whole-well format. Whole-well, rapid cellular analysis enables a
cost-effective solution for the adoption of HCS and HCA into high throughput
"This acquisition fills a gap in our current product portfolio, allowing
us to offer our pharmaceutical research customers fast and simple cellular
analysis with a line of instrumentation that images the whole well at true
high throughput screening rates," said Andy Boorn, president of MDS Analytical
Technologies. "There are currently fourteen IsoCyte instruments installed at
academic, biotech and pharmaceutical companies in North America. With our
extensive global sales force, we have the ability to bring this novel product
to a wider global market."
"We are very excited about this opportunity for Blueshift Biotechnologies
to merge into a world-class company like MDS Analytical Technologies," stated
Evan Cromwell, president of Blueshift Biotechnologies. "The breadth and
strength of its sales and marketing efforts mean that we will be able to
increase awareness of this unique high-throughput imaging tool in new
About MDS Analytical Technologies
MDS Analytical Technologies is a newly established MDS Inc. business unit
and is a world-class organization comprised of two main lines of business. The
Sciex product portfolio offers proven market leadership in mass spectrometry
through its joint ventures with two of the world's leading analytical
instrumentation and life sciences companies, Applied Biosystems, a business of
Applera Corporation, and PerkinElmer Inc. Molecular Devices' product portfolio
is the gold standard in high-performance bioanalytical measurement systems
that accelerate and improve drug discovery and other life sciences research.
Find out more at www.moleculardevices.com or www.mdssciex.com.
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS, Inc.
has more than 5,500 highly skilled people in 29 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
For further information:
For further information: Media: Cheri Salazar, Molecular Devices, now
part of MDS Analytical Technologies, (408) 548-6316, firstname.lastname@example.org;
Investors: Kim Lee, MDS Inc., (416) 675-6777 ext. 34721, email@example.com